Regeneron reports Q2 results at 6:30 AM ET with investors watching Eylea HD's grip on the wet AMD market against Roche's Vabysmo and the growing shadow of Medicare drug price negotiations on its pipeline.
Regeneron :
REGN
REGN
Stock Data
$784.36
$12.25 (1.59%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Regeneron Pharmaceuticals Inc is a biotech firm based in Tarrytown, New York, known for its innovative approach to developing and commercializing medicines for a variety of diseases. The company's portfolio includes treatments for eye conditions like wet age-related macular degeneration, skin diseases such as atopic dermatitis, and other serious ailments including asthma, cardiovascular disease, and certain cancers. Regeneron is also notable for its contributions to infectious disease treatments, including a therapy for COVID-19 and the Ebola virus. Founded in 1988, Regeneron stands out for its commitment to addressing unmet medical needs.
Latest Activity
All Regeneron Articles
248 Articles